

American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity





The total number of the 19 noted anatomic regions in which the patient has had pain over the last week equals the widespread pain index.

Medication	Pros	Cons
TCAs (amitriptyline, ~cyclobenzapri ne)	Cheap, often effective, available	Amitriptyline: (Older patients at increased risk) - Anticholinergic effects - ECG changes - CNS depression - Orthostatic hypotension Cyclobenzaprine – mostly drowsiness
SNRIs (duloxetine, venlafaxine, milnacipran)	Fewer side effects, often better for fatigue, depression	Nausea, dry mouth, constipation, headache, somnolence, dizziness, and insomnia - Venlafaxine not FDA approved for FM. - <u>Milnacipran</u> requires NFDR
Anticonvulsant (pregabalin, gabapentin)	Fewer side effects, Often better for insomnia	 CNS/respiratory depression Hypersensitivity reactions Weight gain SI Pregabalin is more expensive but has better data than gabapentin

Both TCAs and SNRIs cause increased risk of the following antidepressant class effect outcomes: SI, bleeding, fragility fractures, serotonin syndrome